Twist Bioscience Launches Exome 2.0 for Genomics Research
October 20 2021 - 8:00AM
Business Wire
- Best-in-Industry Exome Content and
Performance -
- Enables Lower Sequencing Costs through
Best-in-Class Uniformity -
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced the launch of its
Exome 2.0, featuring the most comprehensive coverage of
protein-coding and noncoding regions of the genome, as well as
best-in-class performance to reduce downstream sequencing
costs.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20211020005355/en/
Twist Exome 2.0, the most comprehensive
coverage of protein-coding and noncoding regions of the genome and
best-in-class performance. (Photo: Business Wire)
“We have been working with Twist for the last three years and
recently adapted the Twist Exome 2.0 for our recent work for
various indications, especially for unexplained developmental
disorders,” said Oliver Wachter of the Center for Human Genetics
and Laboratory Diagnostics in Germany (MVZ-Martinsried GmbH). “The
content, performance and quality are the best we have experienced
from any provider, and we didn’t have to choose between robust
content and performance.”
“Twist continues to expand our portfolio of high-quality,
best-in-class life science tools,” said Emily M. Leproust, Ph.D.,
CEO and co-founder of Twist Bioscience. “With the launch of Exome
2.0, we now offer a complete portfolio of flexible, comprehensive
exome options to support genomics researchers looking to identify
the underpinnings of disease.”
About Twist Exome 2.0
The Twist Exome 2.0 is an exome panel designed with thoughtfully
curated content that includes comprehensive coverage of genes
responsible for rare diseases, inherited disorders, and germline
cancers in humans. With a fully automatable workflow, Twist Exome
2.0 outperformed available exomes on the market today,
demonstrating higher uniformity and a higher on-target rate, as
well as lower drop out and duplicate read rates, resulting in
better data and lower sequencing costs. Exome 2.0 provides
best-in-class coverage of protein-coding regions from major genetic
databases (RefSeq, CCDS, GenCode, Clinvar, ACMG73 and more) as well
as coverage of clinically relevant non-coding pathogenic and likely
pathogenic variants. Twist Exome 2.0 can be customized for a wide
range of applications and uses, while providing workflow
flexibility through Fast Hybridization (<4 hrs) or the new
Standard Hybridization v2 (overnight) reagents. All Twist exomes
contain double-stranded DNA probes for more complete coverage, can
be customized to specific needs, and work with Twist’s library
preparation and target enrichment workflows. Twist Exome 2.0 works
with the recently launched enzymatic fragmentation 2.0 kit to
provide unmatched performance and efficiency in sequencing ready
libraries.
To view other Twist library prep solutions, visit:
https://www.twistbioscience.com/products/ngs/library-preparation/ngs-library-preparation-kits.
To learn more about Twist Exome 2.0 visit:
https://www.twistbioscience.com/products/ngs/fixed-panels/exome2.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein, including but not limited to the ability of Exome 2.0 to
help identify the underpinnings of disease, are forward-looking
statements reflecting the current beliefs and expectations of
management made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause Twist
Bioscience’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
risks and uncertainties of the ability to attract new customers and
retain and grow sales from existing customers; risks and
uncertainties of rapidly changing technologies and extensive
competition in synthetic biology could make the products Twist
Bioscience is developing obsolete or non-competitive; the retention
of employees of acquired companies and the ability of Twist
Bioscience to successfully integrate acquired companies and to
achieve expected benefits, risks of third party claims alleging
infringement of patents and proprietary rights or seeking to
invalidate Twist Bioscience’s patents or proprietary rights; and
the risk that Twist Bioscience’s proprietary rights may be
insufficient to protect its technologies. For a further description
of the risks and uncertainties that could cause actual results to
differ from those expressed in these forward-looking statements, as
well as risks relating to Twist Bioscience’s business in general,
see Twist Bioscience’s risk factors set forth in Twist Bioscience’s
Quarterly Report Form 10-Q filed with the Securities and Exchange
Commission on August 9, 2021, and subsequent filings with the SEC.
Any forward-looking statements contained in this press release
speak only as of the date hereof, and Twist Bioscience specifically
disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211020005355/en/
Twist Bioscience Angela Bitting SVP, Corporate Affairs
925-202-6211 media@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Aug 2024 to Sep 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Sep 2023 to Sep 2024